Patients’ preferences for osteoarthritis treatment: the value of stated-preference studies

Mickael Hiligsmann; Daniel Pinto; Elaine Dennison; Nasser Al-Daghri; Charlotte Beaudart; Jaime Branco; Olivier Bruyère; Philip G. Conaghan; Cyrus Cooper; Gabriel Herrero-Beaumont; Famida Jiwa; Willem Lems; Rene Rizzoli; Thierry Thomas; Nicola Veronese; Jean-Yves Reginster

doi:10.1007/s40520-018-1098-3

Patients’ preferences for osteoarthritis treatment: the value of stated-preference studies

Mickael Hiligsmann, Daniel Pinto, Elaine Dennison, Nasser Al-Daghri, Charlotte Beaudart, Jaime Branco, Olivier Bruyère, Philip G. Conaghan, Cyrus Cooper, Gabriel Herrero-Beaumont, Famida Jiwa, Willem Lems, Rene Rizzoli, Thierry Thomas, Nicola Veronese, Jean-Yves Reginster

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Pages (from-to)	1-3
Journal	Aging Clinical and Experimental Research
Volume	31
Issue number	1
Early online date	2019
DOIs	https://doi.org/10.1007/s40520-018-1098-3
Publication status	Published - 25 Jan 2019

Access to Document

10.1007/s40520-018-1098-3

Cite this

Hiligsmann, M., Pinto, D., Dennison, E., Al-Daghri, N., Beaudart, C., Branco, J., Bruyère, O., Conaghan, P. G., Cooper, C., Herrero-Beaumont, G., Jiwa, F., Lems, W., Rizzoli, R., Thomas, T., Veronese, N., & Reginster, J-Y. (2019). Patients’ preferences for osteoarthritis treatment: the value of stated-preference studies. Aging Clinical and Experimental Research, 31(1), 1-3. https://doi.org/10.1007/s40520-018-1098-3

Hiligsmann, Mickael ; Pinto, Daniel ; Dennison, Elaine ; Al-Daghri, Nasser ; Beaudart, Charlotte ; Branco, Jaime ; Bruyère, Olivier ; Conaghan, Philip G. ; Cooper, Cyrus ; Herrero-Beaumont, Gabriel ; Jiwa, Famida ; Lems, Willem ; Rizzoli, Rene ; Thomas, Thierry ; Veronese, Nicola ; Reginster, Jean-Yves. / Patients’ preferences for osteoarthritis treatment: the value of stated-preference studies. In: Aging Clinical and Experimental Research. 2019 ; Vol. 31, No. 1. pp. 1-3.

@article{f4435ec8b0e3463881b01ea776b6dc05,

title = "Patients{\textquoteright} preferences for osteoarthritis treatment: the value of stated-preference studies",

author = "Mickael Hiligsmann and Daniel Pinto and Elaine Dennison and Nasser Al-Daghri and Charlotte Beaudart and Jaime Branco and Olivier Bruy{\`e}re and Conaghan, {Philip G.} and Cyrus Cooper and Gabriel Herrero-Beaumont and Famida Jiwa and Willem Lems and Rene Rizzoli and Thierry Thomas and Nicola Veronese and Jean-Yves Reginster",

note = "Funding Information: Conflict of interest OB: research supports from Biophytis, IBSA, MEDA, Servier, SMB. PGC is supported in part by the UK NIHR Leeds Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. CC: lecture fees and honoraria from Amgen, Danone, Eli Lilly, GSK, Medtronic, Merck, Nestl{\'e}, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB outside of the submitted work. TT: honorarium for lectures or advisory board from Abbvie, Amgen, Arrow, BMS, Chugai, Expanscience, Gilead, HAC-Pharma, LCA, Lilly, Medac, MSD, Pfizer, Thuasne, TEVA and UCB; research support from Amgen, Bone Therapeutics, Chugai, HAC-Pharma, MSD, Novartis, Pfizer, and UCB. JYR: consulting fees or paid advisory boards from IBSA-Genevrier, Mylan, Radius Health, Pierre Fabre, Teva; lecture fees when speaking at the invitation of sponsor: IBSA-Genevrier, Mylan, CNIEL, Dairy Research Council, Teva; Grant support from industry (all through institution) from IBSA-Genevrier, Mylan, CNIEL, Radius Health. OB research supports from Biophytis, IBSA, MEDA, Servier, SMB. NAD, CB, JB, CC, MH, GHB, FJ, DP, WL, and RR have no conflict of interest relevant to the content of this study. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2019",

month = jan,

day = "25",

doi = "10.1007/s40520-018-1098-3",

language = "English",

volume = "31",

pages = "1--3",

journal = "Aging - Clinical and Experimental Research",

issn = "1594-0667",

publisher = "Springer Verlag",

number = "1",

}

Hiligsmann, M, Pinto, D, Dennison, E, Al-Daghri, N, Beaudart, C, Branco, J, Bruyère, O, Conaghan, PG, Cooper, C, Herrero-Beaumont, G, Jiwa, F, Lems, W, Rizzoli, R, Thomas, T, Veronese, N & Reginster, J-Y 2019, 'Patients’ preferences for osteoarthritis treatment: the value of stated-preference studies', Aging Clinical and Experimental Research, vol. 31, no. 1, pp. 1-3. https://doi.org/10.1007/s40520-018-1098-3

Patients’ preferences for osteoarthritis treatment: the value of stated-preference studies. / Hiligsmann, Mickael; Pinto, Daniel; Dennison, Elaine; Al-Daghri, Nasser; Beaudart, Charlotte; Branco, Jaime; Bruyère, Olivier; Conaghan, Philip G.; Cooper, Cyrus; Herrero-Beaumont, Gabriel; Jiwa, Famida; Lems, Willem; Rizzoli, Rene; Thomas, Thierry; Veronese, Nicola; Reginster, Jean-Yves.

In: Aging Clinical and Experimental Research, Vol. 31, No. 1, 25.01.2019, p. 1-3.

Research output: Contribution to journal › Editorial › Academic › peer-review

TY - JOUR

T1 - Patients’ preferences for osteoarthritis treatment: the value of stated-preference studies

AU - Hiligsmann, Mickael

AU - Pinto, Daniel

AU - Dennison, Elaine

AU - Al-Daghri, Nasser

AU - Beaudart, Charlotte

AU - Branco, Jaime

AU - Bruyère, Olivier

AU - Conaghan, Philip G.

AU - Cooper, Cyrus

AU - Herrero-Beaumont, Gabriel

AU - Jiwa, Famida

AU - Lems, Willem

AU - Rizzoli, Rene

AU - Thomas, Thierry

AU - Veronese, Nicola

AU - Reginster, Jean-Yves

N1 - Funding Information: Conflict of interest OB: research supports from Biophytis, IBSA, MEDA, Servier, SMB. PGC is supported in part by the UK NIHR Leeds Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. CC: lecture fees and honoraria from Amgen, Danone, Eli Lilly, GSK, Medtronic, Merck, Nestlé, Novartis, Pfizer, Roche, Servier, Shire, Takeda and UCB outside of the submitted work. TT: honorarium for lectures or advisory board from Abbvie, Amgen, Arrow, BMS, Chugai, Expanscience, Gilead, HAC-Pharma, LCA, Lilly, Medac, MSD, Pfizer, Thuasne, TEVA and UCB; research support from Amgen, Bone Therapeutics, Chugai, HAC-Pharma, MSD, Novartis, Pfizer, and UCB. JYR: consulting fees or paid advisory boards from IBSA-Genevrier, Mylan, Radius Health, Pierre Fabre, Teva; lecture fees when speaking at the invitation of sponsor: IBSA-Genevrier, Mylan, CNIEL, Dairy Research Council, Teva; Grant support from industry (all through institution) from IBSA-Genevrier, Mylan, CNIEL, Radius Health. OB research supports from Biophytis, IBSA, MEDA, Servier, SMB. NAD, CB, JB, CC, MH, GHB, FJ, DP, WL, and RR have no conflict of interest relevant to the content of this study. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2019/1/25

Y1 - 2019/1/25

UR - http://www.scopus.com/inward/record.url?scp=85059528385&partnerID=8YFLogxK

U2 - 10.1007/s40520-018-1098-3

DO - 10.1007/s40520-018-1098-3

M3 - Editorial

C2 - 30607878

VL - 31

SP - 1

EP - 3

JO - Aging - Clinical and Experimental Research

JF - Aging - Clinical and Experimental Research

SN - 1594-0667

IS - 1

ER -

Patients’ preferences for osteoarthritis treatment: the value of stated-preference studies

Access to Document

Other files and links

Cite this